ABVC News and Press, ABVC BioPharma Inc. From 07/28/20

· Last patient last visit (LPLV) marked the final step toward the completion of ABV-1505 Phase II Part I clinical trial in treatment of adult attention-deficit hyperactivity disorder (ADHD). · Preliminary Phase II Part I results indicated effective dosage and treatmen...

Patient enrollment has been completed for a Phase II Part I clinical trial at the University of California, San Francisco (UCSF) Medical Center Primary objective of Phase II Part I clinical trial is to determine the effective dosage of ABV-1505 in treatment of adult attention-deficit h...

FREMONT, CA, May 21, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- American BriVision (Holding) Corporation (OTCQB: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS and ophthalmology, today said its recently announced private plac...

FREMONT, CA, April 13, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – American BriVision (Holding) Corporation (OTCQB: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS and ophthalmology, today announced it had entered into tw...

Fremont, CA - ( NewMediaWire ) - April 13, 2020 - American BriVision (Holding) Corporation (OTCQB: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS and ophthalmology, today announced it had entered into two financial transactions tha...

PDC-1421, the active ingredient of ABV-1505, is being expanded into Adult ADHD trials following encouraging Phase II trial results in major depressive disorder (MDD) A site monitoring visit for the on-going Phase II Part I trial of ABV-1505 for the treatment of Adult ADHD was conduc...

FREMONT, CA, Feb. 28, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- American BriVision (Holding) Corporation (OTCQB: ABVC), an emerging clinical stage biopharmaceutical company focused on commercializing promising new drugs developed by world-class research institutions such as Sloan Ketteri...

Company Expects to Begin Licensing Vitargus to Marketing Partners in 2020 FREMONT, CA, Feb. 25, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- American BriVision (Holding) Corporation (OTCQB: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/...

  PDC-1421, the active ingredient of ABV-1505, is being expanded into adult ADHD trials following encouraging Phase II trial results in major depressive disorder (MDD)   Phase II Part I trial of ABV-1505 to be conducted at the University of California, San Francisco (UCS...

  PDC-1421 high-dose data meets primary endpoint on MADRS scale in ITT clinical trial population PDC-1421 low-dose and PDC-1421 high-dose each proved safe, were well-tolerated, and had no serious adverse events associated with them in Phase II clinical trial Company is...